The Zacks Analyst Blog Highlights: DreamWorks Animation, Netflix, Valeant Pharmaceuticals International, Allergan, Gilead Sciences and ForestLaboratories

News provided by

Jun 18, 2014, 09:30 ET

CHICAGO, June 18, 2014 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include the DreamWorks Animation SKG Inc. (Nasdaq:DWA-Free Report), Netflix Inc. (Nasdaq:NFLX-Free Report), News Corp. (Nasdaq:NWSA-Free Report), Valeant Pharmaceuticals International, Inc. (NYSE:VRX-Free Report), Allergan, Inc. (NYSE:AGN-Free Report), Gilead Sciences (Nasdaq:GILD-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday's Analyst Blog:

DreamWorks TV Debuts on YouTube

DreamWorks Animation SKG Inc. (Nasdaq:DWA-Free Report) has launched its online TV channel, DreamWorks TV, on Google Inc. controlled YouTube. This multi-platform media service will combine DreamWorks original content library with the digital content delivery expertise of AwesomenessTV, which was acquired by DreamWorks in May 2013.

AwesomenessTV is a premier digital content developer and distributor. It boasts significant Internet offerings and generates revenues primarily from online advertising and distribution of content through media channels such as theatrical, home entertainment and television.

Recently, AwesomenessTV took over Big Frame, another digital content developer and distributor. Notably, DreamWorks has also entered into an online streaming agreement with Netflix Inc. (Nasdaq:NFLX-Free Report).

DreamWorks is diversifying its Feature film segment to mitigate volatility in the film business. Management has decided to invest in key growth areas in order to expand the company's operations into TV, consumer product, digital content and location-based entertainment. DreamWorks believes that exploring all options is the best way to optimally monetize its extensive portfolio of intellectual property rights.

DreamWorks TV primarily targets young viewers between the age group of six and eleven. The network plans to introduce more than a dozen new shows in the first few weeks from original live-action and animated short-form content library of DreamWorks Animation.

The Live Action series will include OMG, Record Setter Kids and Prank My Parents. Animation series will include Jimmy Blue Shorts, Gorillaville, Report Card, Public Pool and Fit Cat Therapist. Additionally, Richie Rich, an original scripted series based on the iconic comic book character will also be available.

DreamWorks currently carries a Zacks Rank #3 (Hold). Another better-ranked stock in the movie/TV production/distribution industry is News Corp. (Nasdaq:NWSA-Free Report), with a Zacks Rank #2 (Buy).

Valeant Receives FDA's Clearance for Restylane

Valeant Pharmaceuticals International, Inc. (NYSE:VRX-Free Report) announced that the FDA issued a marketing clearance for Restylane Silk Injectable Gel with 0.3% Lidocaine.

Restylane Silk Injectable Gel is indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.

Valeant had conducted a clinical study (n=221) on Restylane to evaluate the safety and effectiveness of injections among females with light and dark skin to enhance lip fullness and to improve wrinkles around the lips.

As observed in the study data, 98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection.

We remind investors that in May 2014, Valeant entered into an agreement with Nestle S.A to sell its rights of Restylane, Perlane, Emervel, Sculptra, and Dysport for $1.4 billion in cash.

Valeant had acquired rights to aesthetics products such as Dysport, Perlane, and Restylan through its acquisition of Medicis in Dec 2012.

Earlier in the month, the FDA approved Valeant's New Drug Application (NDA) for Jublia (efinaconazole 10% topical solution) for the treatment of onychomycosis of the toenails.

Meanwhile, Valeant is engaged in a patent infringement suit with Allergan, Inc. (NYSE:AGN-Free Report) for Restylane and Perlane dermal filler products. Allergan has accused Valeant of infringing some of its patents in the U.S.

We note that Allergan recently rejected the revised acquisition offer by Valeant and Pershing Square Capital Management.

Valeant currently has a Rank #3 (Hold). Investors looking for better-ranked stocks in the healthcare sector may consider companies like Gilead Sciences (Nasdaq:GILD-Free Report) and Forest Laboratories Inc. (NYSE:FRX-Free Report). While Gilead Sciences carries a Zacks Rank #1 (Strong Buy), Forest Labs is a Zacks Rank #2 (Buy).

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978. The later formation of the Zacks Rank, a proprietary stock picking system; continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros.

Get the full Report on DWA - FREE

Get the full Report on NFLX - FREE

Get the full Report on NWSA - FREE

Get the full Report on VRX - FREE

Get the full Report on AGN - FREE

Get the full Report on GILD - FREE

Get the full Report on FRX - FREE

Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Logo - http://photos.prnewswire.com/prnh/20101027/ZIRLOGO

SOURCE Zacks Investment Research, Inc.